Skip to Content
You are currently on the new version of our website. Access the old version .
BioengineeringBioengineering
  • Review
  • Open Access

22 October 2022

18 Pages

Engineered Tissue for Cardiac Regeneration: Current Status and Future Perspectives

,
,
,
,
,
and
1
Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
2
Cardiovascular Division, Osaka Police Hospital, Tennoji, Osaka 543-0035, Japan
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.

Abstract

Heart failure (HF) is the leading cause of death worldwide. The most effective HF treatment is heart transplantation, the use of which is restricted by the limited supply of donor hearts. The human pluripotent stem cell (hPSC), including human embryonic stem cell (hESC) and the induced pluripotent stem cells (hiPSC), could be produced in an infinite manner and differentiated into cardiomyocytes (CMs) with high efficiency. The hPSC-CMs have, thus, offered a promising alternative for heart transplant. In this review, we introduce the tissue-engineering technologies for hPSC-CM, including the materials for cell culture and tissue formation, and the delivery means into the heart. The most recent progress in clinical application of hPSC-CMs is also introduced. In addition, the bottleneck limitations and future perspectives for clinical translation are further discussed.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.